Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver
| Status: | Recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/30/2018 |
| Start Date: | November 2014 |
| End Date: | July 2020 |
| Contact: | Mark Supanich, Ph.D. |
| Email: | mark_supanich@rush.edu |
| Phone: | 312.563.4552 |
This project investigates the feasibility of assessing the relative blood volume of
carcinomas in patients with Hepatocellular Carcinoma (HCC) and liver metastases from
pancreatic or colorectal cancer compared to normal liver from DynaCT acquisitions on an
interventional platform.
carcinomas in patients with Hepatocellular Carcinoma (HCC) and liver metastases from
pancreatic or colorectal cancer compared to normal liver from DynaCT acquisitions on an
interventional platform.
This project will enroll patients with non-diffuse liver disease who are candidates for chemo
or radioembolization to treat or manage the disease during an image guided intervention.
Subjects will undergo a CT perfusion study of the liver prior to the radioembolizaiton
mapping procedure or prior to the chemoembolization treatment. During the radioembolization
mapping or chemoembolization procedure, 2 DynaCT acquisitions on the interventional C-arm
will be acquired (the second during an injection of an iodinated contrast material) and will
be processed using Siemens' PBV software to generate blood volume maps. The diagnostic
accuracy of the two approaches to assess the vascularity of the tumors will be assessed.
or radioembolization to treat or manage the disease during an image guided intervention.
Subjects will undergo a CT perfusion study of the liver prior to the radioembolizaiton
mapping procedure or prior to the chemoembolization treatment. During the radioembolization
mapping or chemoembolization procedure, 2 DynaCT acquisitions on the interventional C-arm
will be acquired (the second during an injection of an iodinated contrast material) and will
be processed using Siemens' PBV software to generate blood volume maps. The diagnostic
accuracy of the two approaches to assess the vascularity of the tumors will be assessed.
Inclusion Criteria:
- HCC or metastatic liver disease
- Candidate for radioembolization or chemoembolization
Exclusion Criteria:
- Pregnant
- Iodine allergy
We found this trial at
1
site
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Phone: 312-563-4552
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
